Custom Nucleic Acids Supplier Opens SG$6 Million Manufacturing Facility in Singapore

Already a world leader in custom nucleic acid synthesis, Integrated DNA Technologies (IDT) has expanded its manufacturing capabilities to Singapore. IDT is now able to provide locally-manufactured oligonucleotides to researchers in Singapore and throughout the region from the company’s first synthesis facility in Asia.

In January of 2012, IDT acquired the oligo business of Singapore’s reportedly top supplier 1st BASE Pte. Ltd. Shortly thereafter, IDT began work to create a state-of-the-art hub for oligo manufacturing and support dedicated to the Asian market. IDT completed the nearly SG$6 million project in spring of 2013, and the Singapore company’s synthesis and other processes are now fully integrated with IDT’s operations in the US and Europe.

IDT’s investment in Singapore means that researchers throughout the region can now enjoy quicker delivery of the same high quality custom nucleic acid products they expect from IDT. Through its Asian network of highly skilled sales professionals and 21 appointed distributors, IDT now serves Malaysia, Indonesia, Thailand, Taiwan, the Philippines, Vietnam, Bangladesh, Hong Kong, Nepal, Sri Lanka and Myanmar from its Singapore company. In the coming months, IDT will expand the services it offers from Singapore to include all of the Asia Pacific region’s major markets.

“Our new synthesis and support capabilities in Singapore increase the speed with which we can deliver IDT products to our customers in Asia by two to three days,” noted Trey Martin, Chief Operating Officer at IDT. “Scientists can move forward with their research that much more quickly, which will add to the value IDT already contributes to their important work.”

Said Dr. Joseph A. Walder, Founder and CEO of IDT: “For several years, we’ve looked forward to the day that we could bring to Asia what has made IDT so successful in North America and Europe — the highest quality custom biology products, delivered quickly, at prices that enable new and more research. Our team in Asia now has a world-class facility in Singapore, with the support of IDT’s global infrastructure backing it up.  We’re proud today to offer its benefits to the scientific community in Asia.”

“We strongly welcome IDT’s decision to set up a new oligonucleotide manufacturing facility that supports the scientific community in Singapore and the extended Asia Pacific region. Oligonucleotide manufacturing is knowledge-intensive and requires a high proportion of skilled degree and diploma holders. This new investment will create excellent job opportunities for Singaporeans,” said Kevin Lai, Director, Biomedical Sciences, Singapore Economic Development Board.

Integrated DNA Technologies, Singapore, +65 6775 9187, asiacustcare@idtdna.com, www.idtdna.com.